Finance Watch: Venture Capital Dominates Biopharma Funding So Far In 2022

VC Deals Totaled $9.5bn In Q1, Down From $10.8bn In Q1 2021

Private Company Edition: Biomedtracker found that 53% of financings during the first quarter were venture capital deals versus 32% in Q1 of last year. Also, Qiming closed a $260m fund, Transition Bio raised a $50m series A round, ProfoundBio completed a $70m series A+ and MycoMedica raised $60m.

Finance Watch Private Company — • Source: Shutterstock

Even with less venture capital raised during the first quarter of 2022 than in Q1 of 2021, VC financing has become the most common type of financing for biopharmaceutical firms raising cash in 2022, according to Biomedtracker’s Financing Quarterly Statistics report.

The 126 companies that raised $9.5bn in venture capital accounted for 53% of the $17.9bn raised across all financing types...